CVR - Coronavirus Vaccines R&D Roadmap

Milestone
4.2.e

Standardization

In progress
High priority

Standardize parameters for a CHIM model to assess broadly protective coronavirus vaccines, such as strain selection, standardized panels of immunologic assays, and aligned protocols where feasible, to maintain comparability of data across studies. 

Progress Highlights

Rosenheim 2024 conducted a CHIM to identify blood transcriptional biomarkers that differentiate early and late phases of SARS-CoV-2 respiratory infections. The type 1 interferon markers MX1 and IFI27 (both interferon-stimulated genes) were identified. MX1 demonstrates rapid and transient expression across all cell types, correlating with early infection and viral load. IFI27 shows delayed but sustained expression, primarily in myeloid cells, useful for diagnosing symptomatic infections.